SCHEMBL15030830

SCHEMBL15030830

Cc1ccccc1-c1ccc2c(c1)C1(c3ccccc3Oc3ccccc31)c1cc(-c3ccccc3C)ccc1N2c1ccc2ccc3cccc4ccc1c2c34

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.34
CTSD P07339 2/20 0.34
BACE1 P56817 2/20 0.34
ALDH1A1 P00352 7/20 0.33
CYP3A4 P08684 6/20 0.33
TSHR P16473 5/20 0.33
HSD17B10 Q99714 2/20 0.33
HPGD P15428 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
CLK4 Q9HAZ1 6/20 0.32
CYP2C19 P33261 5/20 0.32
MAPK1 P28482 4/20 0.32
HIF1A Q16665 2/20 0.32
KDM4E B2RXH2 2/20 0.32
ATM Q13315 1/20 0.32
CYP1A2 P05177 5/20 0.31
CYP2D6 P10635 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15030823 0.97 PDK2 (0.36) PDK2CTSDBACE1ALDH1A1CYP3A4
SCHEMBL15030874 0.82 ALDH1A1 (0.40) ALDH1A1CYP3A4TSHRHSD17B10HPGD
SCHEMBL15030887 0.80 PDK2 (0.35) PDK2CTSDBACE1CA12CA9
SCHEMBL15030672 0.80 HTR7 (0.40) PDK2CTSDBACE1ALDH1A1TSHR
SCHEMBL15030835 0.79 PDK2 (0.37) PDK2CTSDBACE1CA12CA9
SCHEMBL15030803 0.78 KDM4E (0.33) ALDH1A1KMT2AMAPK1KDM4EATM
SCHEMBL15030726 0.78 PDK2 (0.38) PDK2CTSDBACE1ALDH1A1TSHR
SCHEMBL15030877 0.77 KDM4E (0.33) ALDH1A1KMT2AMEN1MAPK1KDM4E
SCHEMBL15030729 0.76 CTSD (0.33) PDK2CTSDBACE1CA12CA9
SCHEMBL15030828 0.76 CTSD (0.35) PDK2CTSDBACE1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10305040-B2 Spiro dihydroacridine derivatives and the use thereof as materials for organic electroluminescence devices MERCK PATENT GMBH (DE) 2019-05-28 US disclosed
EP-2780325-B1 SPIRO-DIHYDROACRIDINE DERIVATIVES AND THEIR USE AS MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2016-02-03 EP disclosed
US-20140316134-A1 SPIRO DIHYDROACRIDINE DERIVATIVES AND THE USE THEREOF AS MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES MERCK PATENT GMBH (DE) 2014-10-23 US disclosed
US-20140316134-A1 SPIRO DIHYDROACRIDINE DERIVATIVES AND THE USE THEREOF AS MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES MERCK PATENT GMBH (DE) 2014-10-23 US disclosed
WO-2013083216-A1 SPIRO DIHYDROACRIDINE DERIVATIVES AND THE USE THEREOF AS MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES MERCK PATENT GMBH (DE) 2013-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10305040-B2 Spiro dihydroacridine derivatives and the use thereof as materials for organic electroluminescence devices SORD, ALDH1A1, SDHA PDK2 202/4885CTSD 1951/4885BACE1 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.